RNA polymerase II, I and III subunit FGenealiases: HRBP14.4 · POLRF · RPABC14.4 · RPABC2 · RPB14.4 · RPB6
Q-omics provides the consensus-scored POLR2F profile across patient tissues and cancer cell-line models. POLR2F expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, POLR2F is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, POLR2F RNA expression shows 18,195 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, KIRC, and LSCC as cancer lineages where POLR2F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2F survival associations across molecular data types. POLR2F RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2F RNA expression–survival associations across cancer types. High POLR2F expression shows unfavorable associations in COAD, KIRC and ACC, but favorable associations in LUAD, LGG and ESCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for POLR2F RNA expression.
This table summarizes POLR2F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR2F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2F shows lower tumor expression in UCEC, COAD, BRCA and BLCA and higher tumor expression in KIRC and CHOL. The KIRC box plot shows higher POLR2F RNA expression in tumor versus normal tissue (log2 FC = +0.103, t-test p < 0.001).
This table shows molecular features associated with POLR2F in patient tissues and cancer cell lines. In patient samples, POLR2F shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
